Inogen Inc - INGN STOCK NEWS

Inogen, Inc. (Nasdaq: INGN) has released preliminary revenue estimates for Q4 and full year 2022, projecting revenues between $87.5 million to $88.5 million for Q4, reflecting a year-over-year growth of 14.5% to 15.8%. For the full year, revenue estimates range from $376.7 million to $377.7 million, a growth of 5.2% to 5.5%. CEO Nabil Shabshab mentioned improved productivity as the DTC team's tenure increases, despite macroeconomic challenges. A conference call is scheduled for February 23, 2023, to discuss the financial results.

Inogen, Inc. (NASDAQ: INGN), a medical technology company specializing in respiratory products, has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. President and CEO Nabil Shabshab will present on January 11, 2023, at 10:30 a.m. PT. A live webcast of the presentation will be available on the Inogen Investor Relations website, where archived recordings can also be accessed. Inogen is known for its innovative portable oxygen concentrators designed for patients with chronic respiratory conditions.

Inogen, Inc. (NASDAQ: INGN) has announced participation in two upcoming investor conferences. Management will present at the Stifel 2022 Healthcare Conference on November 15 at 10:20 a.m. ET and the Piper Sandler 34th Annual Healthcare Conference on November 30 at 11:30 a.m. ET. A live webcast and archived recordings of both events will be accessible through the company’s Investor Relations website. Inogen specializes in homecare respiratory products, particularly portable oxygen concentrators.

Inogen reported a total revenue of $105.4 million for Q3 2022, marking a 13.2% increase year-over-year compared to $93.1 million in Q3 2021. On a constant currency basis, revenue growth was 14.5%. However, the company faced a GAAP net loss of $9.5 million and an adjusted net loss of $4.1 million. Total operating expenses rose 28.5% to $53.1 million. Despite these challenges, Inogen maintains a robust cash position of $209.6 million with no debt. For Q4 2022, revenue guidance is projected between $87 million and $92 million, indicating a potential growth of 14% to 20%.

Inogen, Inc. (NASDAQ: INGN), a medical technology company specializing in homecare respiratory products, will announce its third quarter 2022 financial results on November 2, 2022, before the market opens. A conference call is scheduled for 5:30 am PT / 8:30 am ET on the same day, accessible via US domestic and international dialing. Investors can also tune in to a live webcast on Inogen's Investor Relations website. A replay will be available after the call until November 16, 2022, using the provided contact details.

Inogen, a medical technology company, reported total revenue of $103.4 million for Q2 2022, an increase of 1.8% year-over-year. On a constant currency basis, revenue rose 3.6%. The company experienced a net loss of $3.4 million, contrasting with a net income of $5.1 million in Q2 2021. Despite challenges, Inogen maintains a strong cash position of $223.6 million. For Q3 2022, revenue guidance is projected between $97 million and $100 million, reflecting a potential growth of 4% to 7% year-over-year.

Inogen, Inc. (Nasdaq: INGN) announced it will release its second quarter 2022 financial results on August 4, 2022. A conference call will be held at 2:00 pm PT/5:00 pm ET for discussion of the results. US callers can dial (877) 841-3961, while international callers should use (201) 689-8589. The call will also be available as a replay starting August 4, 2022, at 4:00 pm PT to August 18, 2022. Inogen specializes in innovative respiratory products, particularly portable oxygen concentrators for chronic respiratory conditions.

Inogen, Inc. has appointed Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning, effective May 23, 2022. CEO Nabil Shabshab expressed enthusiasm about Agnes's extensive experience in medical technology and life sciences, emphasizing her skill in engaging with shareholders. Agnes has previously held investor relations roles at Butterfly Network, Fluidigm, and ResMed, and she holds an MBA from Kellogg School of Management. This appointment aims to enhance Inogen's strategic capabilities and drive shareholder value.

Inogen, Inc. reported Q1 2022 total revenue of $80.4 million, down 7.5% year-over-year due to supply chain issues. However, revenue increased 5.2% sequentially from Q4 2021. Domestic direct-to-consumer sales rose 12.2% to $34.4 million, while business-to-business sales dropped 83.4% to $5.1 million. International business-to-business revenue surged 77.7% to $27.9 million. A net loss of $14.2 million was reported, with adjusted loss per diluted share of $0.39. The company did not provide revenue guidance for 2022, citing ongoing market uncertainties.